Epilepsy represents the most common maternal neurological disorder requiring continuous treatment during pregnancy. Maintaining optimum seizure control is an important objective in pregnancy, and the majority of women with epilepsy will need to continue antiepileptic drugs (AEDs). AEDs are frequently used to treat several other conditions, such as headaches and mood disorders. They have been associated with an increased risk of congenital malformations, minor anomalies, congenital syndrome and development disorders. This risk seems to be higher among women using polypharmacy and valproic acid. Neural tube defects are associated with valproic acid and carbamazepine exposure. New AEDs seem to have a less teratogenic effect, but human experience is still limited. The purpose of this review is to provide an update on AED exposure in pregnancy, focusing on pharmacokinetics and transplacental transport.

de Santis, M., de Luca, C., Mappa, I., Cesari, E., Quattrocchi, T., Spagnuolo, T., et al. (2011). Antiepileptic drugs during pregnancy: Pharmacokinetics and transplacental transfer. CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 12(5), 781-788 [10.2174/138920111795470958].

Antiepileptic drugs during pregnancy: Pharmacokinetics and transplacental transfer

Mappa I.;
2011-01-01

Abstract

Epilepsy represents the most common maternal neurological disorder requiring continuous treatment during pregnancy. Maintaining optimum seizure control is an important objective in pregnancy, and the majority of women with epilepsy will need to continue antiepileptic drugs (AEDs). AEDs are frequently used to treat several other conditions, such as headaches and mood disorders. They have been associated with an increased risk of congenital malformations, minor anomalies, congenital syndrome and development disorders. This risk seems to be higher among women using polypharmacy and valproic acid. Neural tube defects are associated with valproic acid and carbamazepine exposure. New AEDs seem to have a less teratogenic effect, but human experience is still limited. The purpose of this review is to provide an update on AED exposure in pregnancy, focusing on pharmacokinetics and transplacental transport.
2011
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/40 - GINECOLOGIA E OSTETRICIA
English
Antiepileptic drugs
epilepsy
pharmacokinetics
placenta
placental transfer
pregnancy
teratology
Animals
Anticonvulsants
Epilepsy
Female
Humans
Placenta
Pregnancy
Pregnancy Complications
Maternal-Fetal Exchange
de Santis, M., de Luca, C., Mappa, I., Cesari, E., Quattrocchi, T., Spagnuolo, T., et al. (2011). Antiepileptic drugs during pregnancy: Pharmacokinetics and transplacental transfer. CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 12(5), 781-788 [10.2174/138920111795470958].
de Santis, M; de Luca, C; Mappa, I; Cesari, E; Quattrocchi, T; Spagnuolo, T; Visconti, D; Caruso, A
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/276641
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 8
social impact